Sodium Butyrate For Improving Cognitive Function In Schizophrenia
Status:
Withdrawn
Trial end date:
2020-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this grant is to evaluate the efficacy of sodium butyrate as a novel treatment
for cognitive deficits in schizophrenia (SZ). The aims will be to evaluate its effects on
improving symptoms and functioning in SZ, and the relationship of the drug's clinical effects
to epigenetic and inflammation related biochemical changes.